Citations

Mayo Clinic

Showing 10 of 108599 citations.

Conditional, Tissue-Specific CRISPR/Cas9 Vector System in Zebrafish Reveals the Role of Nrp1b in Heart Regeneration
Angom, Ramcharan Singh , Wang, Ying , Wang, Enfeng , Dutta, Shamit K., Singh Angom, Ramcharan , Dutta, Shamit Kumar, Mukhopadhyay, Debabrata , Wang, Ying , Mukhopadhyay, Debabrata

Arteriosclerosis, Thrombosis, and Vascular Biology | August 31, 2023 | Volume: 43 | Issue: 10 | Pages: 1921-1934

10.1161/atvbaha.123.319189 | PMID 37650323 Get It

BACKGROUND: CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) technology-mediated genome editing has significantly improved the targeted inactivation of genes in vitro and in vivo in many organisms. Neuropilins play crucial roles in zebrafish heart regeneration, heart failure in mice, and electrical remodeling after myocardial infarction in rats. But the cell-specific functions of nrp1 have not been described before. In this study, we have investigated the role of nrp1 isoforms, including nrp1a and nrp1b , in cardiomyocytes during cardiac injury and regeneration in adult zebrafish hearts. METHODS: In this study, we have reported a novel CRISPR-based vector system for conditional tissue-specific gene ablation in zebrafish. Specifically, the cardiac-specific cmlc2 promoter drives Cas9 expression to silence the nrp1 gene in cardiomyocytes in a heat-shock inducible manner. This vector system establishes a unique tool to regulate the gene knockout in both the developmental and adult stages and hence widens the possibility of loss-of-function studies in zebrafish at different stages of development and adulthood. Using this approach, we investigated the role of neuropilin isoforms nrp1a and nrp1b in response to cardiac injury and regeneration in adult zebrafish hearts. RESULTS: We observed that both the isoforms ( nrp1a and nrp1b ) are upregulated after the cryoinjury. Interestingly, the nrp1b knockout significantly delayed heart regeneration and impaired cardiac function in the adult zebrafish after cryoinjury, demonstrated by reduced heart rate, ejection fractions, and fractional shortening. In addition, we show that the knockdown of nrp1b but not nrp1a induces activation of the cardiac remodeling genes in response to cryoinjury. CONCLUSIONS: To our knowledge, this study is novel where we have reported a heat-shock–mediated conditional knockdown of nrp1a and nrp1b isoforms using CRISPR/Cas9 technology in the cardiomyocyte in zebrafish and furthermore have identified a crucial role for the nrp1b isoform in zebrafish cardiac remodeling and eventually heart function in response to injury.
Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery
Neth, Bryan J. , Sairaj, Revathi Thirumushi, Loron, Ali Gharibi , Hirte, Renee, Riviere-Cazaux, Cécile , Ruff, Michael W. , Gharibi Loron, Ali, Rahman, Masum , Riviere-Cazaux, Cecile , Neth, Byran J. , Winters, Jeffrey L. , Burns, Terry C.

Neuro-Oncology Practice | August 30, 2023 | Volume: 10 | Issue: 6 | Pages: 592-595

10.1093/nop/npad053 | PMID 38009115 Get It

Abstract Background Bevacizumab is commonly used to manage cerebral edema associated with brain tumors. However, its long half-life poses challenges for patients requiring urgent surgery due to wound complications. We present a case of utilizing therapeutic plasma exchange (TPE) to remove bevacizumab in a patient with recurrent glioblastoma requiring urgent surgery. Methods A 58-year-old male with recurrent glioblastoma, IDH-wildtype, presented with clinical and radiographic concern for ventriculitis requiring urgent wound washout only 4 days after his last bevacizumab infusion. TPE was performed for 3 sessions after surgery using a centrifugation-based cell separator. Replacement fluids included normal serum albumin, normal saline, and fresh frozen plasma. Bevacizumab levels were quantified using an enzyme-linked immunoabsorbent assay before and after each TPE session. Results TPE effectively removed bevacizumab, enabling safe surgery without new complications. Plasma bevacizumab levels decreased from 1087.63 to 145.35 ng/mL (13.4% of original) by the end of the last TPE session. This decline is consistent with nearly 3 half-lives, which compares favorably to the expected timeline of natural decline given the 21-day half-life. Conclusions We report a complex clinical scenario of a patient requiring urgent wound washout 4 days after last bevacizumab infusion for CNS infection. Surgery was successfully performed without new complications with use of TPE to remove bevacizumab immediately following surgery. This case highlights the feasibility of this approach, which may be utilized effectively in patients requiring surgery after having recently received bevacizumab.
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Bashey, Asad, Foran, James M. , Mawad, Raya, Short, Nicholas J. , Yılmaz, Musa , Kantarjian, Hagop M. , Odenike, Olatoyosi , Patel, Anand , Garcha, Raman, Ainsworth, William B., Clynes, Raphael , Kanodia, Jitendra , Ding, Ying , Li, Huajiang, Kye, Steve, Short, Nicholas , Patel, Anand , Mims, Alice S , Yilmaz, Musa , Kantarjian, Hagop , Ravandi, Farhad , Stock, Wendy

Blood Advances | August 30, 2023 | Volume: 7 | Issue: 21 | Pages: 6492-6505

10.1182/bloodadvances.2023010956 | PMID 37647601 Get It

Abstract Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells. This phase 1 study’s primary objectives were safety and tolerability and identification of a maximum tolerated dose/recommended dose for use as monotherapy in patients with relapsed/refractory AML. Identification of a recommended phase 2 vibecotamab dose comprised 3 step-up doses (Week 1), which were noted to reduce cytokine response syndrome (CRS), followed by weekly dosing (1.7 μg/kg, Cohort -1D). In 16 of 120 patients, at least 1 treatment-emergent adverse event was classified as a dose-limiting toxicity. CRS, the most common adverse event (59.2%), managed with premedication, were mostly ≤grade 2. A secondary objective was assessment of efficacy in patients with CD123-expressing leukemias. A total of 10 of 111 (9.0%) efficacy-evaluable patients with AML achieved an overall response of morphologic leukemia-free state or better with an overall objective response rate (ORR) of 9.0%. Response was only observed in patients receiving a target dose of 0.75 μg/kg or higher (n = 87) in which the efficacy-evaluable ORR was 11.5%. Response was associated with lower baseline blast counts in blood and bone marrow (<25%) suggesting potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT02730312.
Butterfly Effect: Does the Sex of Red Blood Cell Donors Influence Recipient Mortality?
Su, Leon , Shah, Surbhi, Adamski, Jill

The Hematologist | August 30, 2023 | Volume: 20 | Issue: 5 | Pages: No page available

10.1182/hem.v20.5.202356 Get It

“Trident Sign” in Primary CNS B-Cell Spinal Cord Lymphoma
Griffin, Kim J. , Tolédano, Michel B. , Toledano, Michel , Mustafa, Rafid , Toledano, Michel, Flanagan, Eoin P.

Neurology | August 30, 2023 | Volume: 101 | Issue: 19 | Pages: 857-858

10.1212/wnl.0000000000207671 | PMID 37648533 Get It

Hemicord White Matter Enhancement and the Croissant Sign in Cervical Spondylotic Myelopathy
Li, Xiaoyang , Krecke, Karl N. , Weinshenker, Brian G. , Ζεκερίδου, Αναστασία , Toledano, Michel , Weinshenker, Brian G , Clarke, Michelle J. , Flanagan, Eoin P.

Neurology | August 30, 2023 | Volume: 101 | Issue: 21 | Pages: 968-969

10.1212/wnl.0000000000207793 | PMID 37648534 Get It

Integrated Urology and Primary Care Model Improves Outcomes for Men With Testosterone Deficiency
Nguyen, Vi , Berrios, Susana E., Leonard, Austin, Byrne, Eileen, Martin, Leslie, Hsieh, Tung-Chin, Byrne, Eileen R. , Berrios, Susana , Patel, Darshan P. , Martin, Leslie, Hsieh, Tung‐Chin

Urology Practice | August 30, 2023 | Volume: 10 | Issue: 6 | Pages: 673-678

10.1097/upj.0000000000000447 | PMID 37647136 Get It

Caregiver’s perceptions of COVID-19 vaccination, and intention to vaccinate their children against the disease: a questionnaire based qualitative study
Yasmin, Farah , Kumari, Kanchan, Saleem, Kanza, Lareeb, Iqra , Ashfaq, Rija, Bashar, Nermeen , Najeeb, Hala , Asghar, Muhammad Sohaib , Saleem, Kanza, Shaikh, Asim , Ahmed, Bilal

Annals of Medicine & Surgery | August 30, 2023 | Volume: 85 | Issue: 10 | Pages: 4757-4763

10.1097/ms9.0000000000001165 | PMID 37811020 Get It

Coronavirus disease 2019 (COVID-19) vaccine side effects have an important role in the hesitancy of the general population toward vaccine administration. Another reason for vaccine hesitancy might be that healthcare professionals may not address their concerns regarding vaccines appropriately. Regardless, hesitancy in the form of delay, refusal, or acceptance with doubts about its usefulness can limit the downward trajectory of the COVID-19 pandemic. Therefore, the authors conducted a national cross-sectional study (n=306) to assess causes and concerns for vaccine hesitancy in caregivers in Pakistan toward getting their children vaccinated. The questions identified caregivers by socioeconomic demographics, perceived COVID-19 pandemic severity, and concerns toward the COVID-19 vaccine. The majority of the participants were 45–59 years of age (42.8%) with a mean age of 36.11 years (SD: 7.81). A total of 80% of these participants were willing to vaccinate their child with any COVID-19 vaccine. Present comorbidities had a frequency of 28.4% (n=87/306) and only 26.9% (n=66/245) participants were willing to vaccinate their child. Participants with high social standing were 15.4% (n=47/306) with the majority of them being willing to vaccinate their children (45/47). Socioeconomic status (OR:2.911 [0.999–8.483]), and the child’s vaccinations being up to date (OR:1.904 [1.078–3.365]) were found to be independent factors for caregivers to be willing to vaccinate their child. Around 62% (n=191/306) were not willing to vaccinate due to the concern for side effects, 67.6% (n=207/306) were not willing because they did not have ample information available, and 51% (n=156/306) were not willing as they were concerned about vaccine effectiveness. Further studies on vaccine safety in the pediatric population are required to improve caregivers’ perceptions.
Portal vein thrombosis in a 10-month-old infant as a complication of neonatal umbilical catheterization: a case report
Haddad, Salim, Swaid, Komait , Martini, Nafiza , Alkouri, Lina, Mansour, Marah , Haddad, Sultaneh

Annals of Medicine & Surgery | August 30, 2023 | Volume: 85 | Issue: 10 | Pages: 5158-5162

10.1097/ms9.0000000000001173 | PMID 37811093 Get It

Introduction: Esophageal varices bleeding after portal hypertension is a rare condition in children but is associated with significant morbidity and mortality. Neonatal umbilical catheterization is one of the risk factors for the development of portal vein thrombosis (PVT) and portal hypertension. Case presentation: Neonatal umbilical catheterization was used here to provide appropriate treatment for postpartum sepsis. Color Doppler revealed an approximate total obstruction of the portal vein, and endoscopy showed esophageal varices. The patient was sequentially managed with endoscopic sclerotherapy. Discussion: The manifestations associated with PVT (like splenomegaly and bleeding esophageal varices) have been detected in a 10-month-old, which is considered a relatively young age according to the medical literature review. Conclusion: Using umbilical vein catheterization in neonates may be associated with several complications, including PVT. This case report describes a rare instance of portal hypertension complicated by bleeding esophageal varices in a 10-month-old infant who had undergone newborn umbilical catheterization.
Technical Recommendations for Computed Tomography Guidance of Intervention in the Right Ventricular Outflow Tract: Native RVOT, Conduits, and Bioprosthetic Valves
García, Santiago , Blanke, Phillip, Martin, Mary Hunt , Zahn, Evan M. , Crean, Andrew , Overman, David M. , Hanneman, Kate , Semple, Thomas , Overman, David, Hanneman, Kate , Han, Bo , Aboulhosn, Jamil , Hamilton-Craig, Christian R , Armstrong, Aimee K.

World Journal for Pediatric and Congenital Heart Surgery | August 30, 2023 | Volume: 14 | Issue: 6 | Pages: 761-791

10.1177/21501351231186898 | PMID 37647270 Get It

This consensus document for the performance of cardiovascular computed tomography (CCT) to guide intervention in the right ventricular outflow tract (RVOT) in patients with congenital heart disease (CHD) was developed collaboratively by pediatric and adult interventionalists, surgeons, and cardiac imagers with expertise specific to this patient subset. The document summarizes definitions of RVOT dysfunction as assessed by multimodality imaging techniques and reviews existing consensus statements and guideline documents pertaining to indications for intervention. In the context of this background information, recommendations for CCT scan acquisition and a standardized approach for reporting prior to surgical or transcatheter pulmonary valve replacement are proposed and presented. It is the first Imaging for Intervention collaboration for CHD patients and encompasses imaging and reporting recommendations prior to both surgical and percutaneous pulmonary valve replacement.